BioNTech and its U.S. partner Pfizer have already begun manufacturing Covid-19 boosters that are adapted for multiple Omicron sub variants including BA.1, BA.4 and BA.5.
Vaccine Targeting Fast-Spreading Omicron Subvariants Could Be Ready For Fall As Pfizer, BioNTech Announce Trials
